8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

Ma S, Li Z, Gong S, Lu C, Li X, Li Y

Bioeffects Seen

Authors not listed · 2023

Share:

This cancer drug study was incorrectly classified as EMF research, highlighting database accuracy issues.

Plain English Summary

Summary written for general audiences

This study appears to be incorrectly categorized in the EMF Research Hub database. The research actually tested D-1553 (garsorasib), an oral cancer drug, in 79 Chinese patients with a specific type of lung cancer. The drug showed promising results with a 40.5% response rate and manageable side effects.

Why This Matters

This study highlights a critical issue with EMF research databases and scientific classification systems. When cancer treatment studies get miscategorized as EMF research, it creates confusion and undermines the credibility of legitimate electromagnetic field health investigations. The reality is that proper study classification is essential for understanding the true scope of EMF health effects. This misclassification demonstrates why you need to carefully evaluate the actual content of research rather than relying solely on database tags or keywords. Real EMF research examines how electromagnetic fields from sources like cell phones, Wi-Fi, or power lines affect biological systems, not pharmaceutical interventions for genetic mutations.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2023). Ma S, Li Z, Gong S, Lu C, Li X, Li Y.
Show BibTeX
@article{ma_s_li_z_gong_s_lu_c_li_x_li_y_ce3358,
  author = {Unknown},
  title = {Ma S, Li Z, Gong S, Lu C, Li X, Li Y},
  year = {2023},
  doi = {10.1016/j.jtho.2023.03.015},
  
}
DOI: 10.1016/j.jtho.2023.03.015PubMed: 36948246

Quick Questions About This Study

This appears to be a database classification error. The study examines a pharmaceutical cancer treatment (D-1553/garsorasib) for lung cancer patients, not electromagnetic field exposures or their health effects.
The oral cancer drug achieved a 40.5% objective response rate in 74 evaluable patients with KRAS G12C-mutated lung cancer, with most patients tolerating the treatment well despite some side effects.
Among 79 treated patients, 30 patients (38.0%) experienced grade 3 or 4 adverse events, though researchers reported these were generally manageable and patients tolerated treatment well.
The median progression-free survival was 8.2 months overall, with 7.6 months at the recommended phase 2 dose of 600 mg twice daily in this Chinese patient population.
In patients with brain metastasis, the drug achieved a 17% objective response rate and 100% disease control rate, showing some activity even in this challenging patient population.